Windward Bio

📍 Basel, Switzerland👥 44 employees💰 Last funded May 2026
Biotechnology Research🌐 windwardbio.com
Website LinkedIn
Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting anti-TSLP monoclonal antibody currently in a Phase 2 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific, which has broad therapeutic application across immunological diseases. The company is building a pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Windward Bio launched in January 2025 with a $200M Series A led by top-tier investors.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Windward Bio?
Windward Bio has 1 investors on record on gritt.io.
When did Windward Bio last raise funding?
The most recent investment in Windward Bio recorded on gritt.io was in May 2026.
What industry is Windward Bio in?
Windward Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Windward Bio based?
Windward Bio is headquartered in Basel, Switzerland.